New-onset persistent left bundle branch block following sutureless aortic valve replacement.


Journal

Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087

Informations de publication

Date de publication:
22 12 2022
Historique:
received: 31 03 2022
accepted: 30 06 2022
pubmed: 17 7 2022
medline: 27 12 2022
entrez: 16 7 2022
Statut: epublish

Résumé

To evaluate the incidence, predictive factors and prognostic value of new-onset persistent left bundle branch block (NOP-LBBB) in patients undergoing sutureless surgical aortic valve replacement (SU-SAVR). A total of 329 consecutive patients without baseline conduction disturbances or previous permanent pacemaker implantation (PPI) who underwent SU-SAVR with the Perceval valve (LivaNova Group, Saluggia, Italy) in two centres from 2013 to 2019 were included. Patients were on continuous ECG monitoring during hospitalisation and 12-lead ECG was performed after the procedure and at hospital discharge. NOP-LBBB was defined as a new postprocedural LBBB that persisted at hospital discharge. Baseline, procedural and follow-up clinical and echocardiography data were collected in a dedicated database. New-onset LBBB was observed in 115 (34.9%) patients, and in 76 (23.1%) persisted at hospital discharge. There were no differences in baseline and procedural characteristics between patients with (n=76) and without (n=253) NOP-LBBB. After a median follow-up of 3.3 years (2.3-4.4 years), patients with NOP-LBBB had a higher incidence of PPI (14.5% vs 6.3%, p=0.016), but exhibited similar rates of all-cause mortality (19.4% vs 19.2%, p=0.428), cardiac mortality (8.1% vs 9.4%, p=0.805) and heart failure readmission (21.0% vs 23.2%, p=0.648), compared with the no/transient LBBB group. NOP-LBBB was associated with a decrease in left ventricular ejection fraction (LVEF) at 1-year follow-up (delta: -5.7 vs +0.2, p<0.001). NOP-LBBB occurred in approximately a quarter of patients without prior conduction disturbances who underwent SU-SAVR and was associated with a threefold increased risk of PPI along with a negative impact on LVEF at follow-up.

Identifiants

pubmed: 35842233
pii: heartjnl-2022-321191
doi: 10.1136/heartjnl-2022-321191
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

143-150

Informations de copyright

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: JR-C is consultant for and has received institutional research grants from Edwards Lifesciences, Medtronic and Boston Scientific.

Auteurs

Victoria Vilalta (V)

Department of Cardiology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.

Germán Cediel (G)

Department of Cardiology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

Siamak Mohammadi (S)

Department of Cardiology and Cardiac Surgery, Quebec Heart and Lung Institute, Quebec City, Quebec, Canada.

Helena López (H)

Department of Cardiology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

Dimitri Kalavrouziotis (D)

Department of Cardiology and Cardiac Surgery, Quebec Heart and Lung Institute, Quebec City, Quebec, Canada.

Helena Resta (H)

Department of Cardiology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

Eric Dumont (E)

Department of Cardiology and Cardiac Surgery, Quebec Heart and Lung Institute, Quebec City, Quebec, Canada.

Pierre Voisine (P)

Department of Cardiology and Cardiac Surgery, Quebec Heart and Lung Institute, Quebec City, Quebec, Canada.

François Philippon (F)

Department of Cardiology and Cardiac Surgery, Quebec Heart and Lung Institute, Quebec City, Quebec, Canada.

Claudia Escabia (C)

Department of Cardiology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

Andrea Borrellas (A)

Department of Cardiology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

Alberto Alperi (A)

Department of Cardiology and Cardiac Surgery, Quebec Heart and Lung Institute, Quebec City, Quebec, Canada.

Eduard Fernandez-Nofrerias (E)

Department of Cardiology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

Xavier Carrillo (X)

Department of Cardiology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

Vassili Panagides (V)

Department of Cardiology and Cardiac Surgery, Quebec Heart and Lung Institute, Quebec City, Quebec, Canada.

Antoni Bayes-Genis (A)

Department of Cardiology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.

Josep Rodés-Cabau (J)

Department of Cardiology and Cardiac Surgery, Quebec Heart and Lung Institute, Quebec City, Quebec, Canada josep.rodes@criucpq.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH